WO2023090974A1 - 아릴에텐 화합물의 제조방법 - Google Patents
아릴에텐 화합물의 제조방법 Download PDFInfo
- Publication number
- WO2023090974A1 WO2023090974A1 PCT/KR2022/018469 KR2022018469W WO2023090974A1 WO 2023090974 A1 WO2023090974 A1 WO 2023090974A1 KR 2022018469 W KR2022018469 W KR 2022018469W WO 2023090974 A1 WO2023090974 A1 WO 2023090974A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- reaction
- mol
- preparing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000005727 Friedel-Crafts reaction Methods 0.000 claims description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 5
- -1 lithium aluminum tetrahydride Chemical compound 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 238000006519 Mcmurry reaction Methods 0.000 claims description 3
- 230000001335 demethylating effect Effects 0.000 claims description 3
- 238000006722 reduction reaction Methods 0.000 claims description 3
- 238000010520 demethylation reaction Methods 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000007810 chemical reaction solvent Substances 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 108020004067 estrogen-related receptors Proteins 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102100020886 Sodium/iodide cotransporter Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- PQLAYKMGZDUDLQ-UHFFFAOYSA-K aluminium bromide Chemical compound Br[Al](Br)Br PQLAYKMGZDUDLQ-UHFFFAOYSA-K 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 108010013351 sodium-iodide symporter Proteins 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- PUGUQINMNYINPK-UHFFFAOYSA-N tert-butyl 4-(2-chloroacetyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)CCl)CC1 PUGUQINMNYINPK-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
Definitions
- the present invention relates to a method for preparing an arylethene compound, and more particularly, to a method for preparing an arylethene compound in high yield and high purity.
- Estrogen Related Receptor is one of the orphan nuclear receptors whose natural ligand that binds has not yet been identified. do.
- Korean Patent Laid-open Publication No. 10-2018-0001240 discloses that the arylethene compound represented by Formula 1 below has a very high inhibitory activity against ERR ⁇ , thereby preventing diseases mediated by ERR ⁇ , particularly obesity, diabetes, hyperlipidemia, fatty liver, or arteriosclerosis. It can be used to prevent or treat metabolic diseases such as sclerosis and retinopathy, and regulates the expression of endogenous ERR ⁇ protein to regulate mitogen-activated protein kinase (MAP kinase) and the function of sodium iodide symporter (NIS). It has been reported that radioactive iodine uptake can be enhanced in the treatment of thyroid cancer by increasing membrane-localized NIS by improving the membrane-localized NIS.
- MAP kinase mitogen-activated protein kinase
- NIS sodium iodide symporter
- One object of the present invention is to provide a method for stereoselectively preparing the arylethene compound represented by Formula 1.
- Another object of the present invention is to provide a method for producing a high-purity arylethene compound represented by Formula 1 in high yield through a simple process.
- One embodiment of the present invention relates to a method for producing a compound represented by Formula 1, the method for producing the present invention
- reaction Scheme 1 The method described in Reaction Scheme 1 below is merely an example of a method typically used, and reaction reagents, reaction conditions, etc. may be changed as needed.
- the compound of Formula 4 may be prepared by subjecting the compound of Formula 2 to a compound of Formula 3 and a Friedel-Crafts reaction.
- the Friedel-Crafts reaction may be carried out in the presence of a Lewis acid.
- Aluminum chloride, aluminum bromide, etc. may be used as the Lewis acid, and aluminum chloride (AlCl 3 ) is particularly preferred.
- the reaction temperature is preferably room temperature, and dichloromethane, diethyl ether, etc. may be used as the reaction solvent.
- the compound of Formula 6 can be prepared by combining the compound of Formula 4 with the compound of Formula 5 under basic conditions.
- Potassium carbonate, cesium carbonate, sodium carbonate, etc. may be used as the base, and potassium carbonate (K 2 CO 3 ) is particularly preferred.
- the base may be used in an amount of 1.5 to 2.5 equivalents, preferably about 2 equivalents, based on 1 equivalent of the compound of Formula 4.
- the reaction temperature is preferably 140 to 180°C, more preferably 150 to 170°C.
- N-methylpyrrolidone dimethyl sulfoxide, etc.
- NMP N-methylpyrrolidone
- the compound of Formula 7 can be prepared by demethylating the compound of Formula 6.
- the demethylation reaction may be performed using HBr, HCl, boron tribromide, aluminum tribromide, or the like, and HBr is particularly preferred.
- the reaction temperature is preferably under reflux conditions, and acetic acid (AcOH) may be used as the reaction solvent.
- the compound of Formula 8 can be prepared by reacting the compound of Formula 7 with pivaroyl chloride (PivCl) under basic conditions.
- Triethylamine 4-dimethylaminopyridine, imidazole, 2,6-lutidine, etc. may be used as the base, and triethylamine (TEA) is particularly suitable.
- TAA triethylamine
- the reaction temperature is preferably room temperature, and dichloromethane, chloroform, etc. may be used as the reaction solvent.
- the compound of Formula 10 can be prepared by performing a McMurry reaction between a compound of Formula 8 and a compound of Formula 9.
- the McMurray reaction may be performed in the presence of TiCl 4 and Zn.
- the reaction temperature is preferably under reflux conditions, and tetrahydrofuran, dichloromethane, toluene, etc. may be used as the reaction solvent, and tetrahydrofuran is particularly preferred.
- the compound of Formula 1 can be prepared by subjecting the compound of Formula 10 to a reduction reaction.
- the reduction reaction may be performed using lithium aluminum tetrahydride, sodium bis(2-methoxyethoxy)aluminum dihydride, diisobutylaluminum hydride (DIBAL-H), or the like.
- DIBAL-H diisobutylaluminum hydride
- LAH lithium aluminum tetrahydride
- the reaction temperature is preferably about 0 °C, and tetrahydrofuran, methylene chloride, toluene, etc. may be used as the reaction solvent, and tetrahydrofuran is particularly preferred.
- One embodiment of the present invention relates to a method for preparing dihydrochloride of the compound of formula 1 by reacting the compound of formula 1 obtained by the above preparation method with hydrogen chloride.
- the reaction temperature is preferably room temperature, and methanol, 1,4-dioxane, etc. may be used as the reaction solvent, and methanol is particularly preferred.
- the dihydrochloride salt of the compound of Formula 1 thus prepared has a purity of 99.3% or more, effectively removing the Z isomer.
- the high-purity arylethene compound represented by Chemical Formula 1 can be mass-produced in high yield through a simple process.
- a compound of Formula 2 (12.5 kg, 115 mol, 1.00 eq ) and a compound of Formula 3 (18.4 kg, 115 mol, 1.00 eq ) were dissolved in dichloromethane (165 kg) and AlCl 3 (16.2 kg, 121 mol, 1.05 eq ) was added at -5 ⁇ 5 ° C.
- the reaction mixture was stirred at 20-25 o C for 10 hours, then added to HCl solution (aq, 1.60 mol L -1 , 100 L, 160 mol), and after layer separation, the aqueous layer was extracted with dichloromethane (50 L) did The combined organic layers were washed with NaHCO 3 (50 L), then brine (50 L). It was then dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was treated with petroleum ether (50 L), filtered and concentrated to give compound 4 (22.9 kg, 99.5 mol, 86.0% yield) as a red solid.
- a compound of formula 6 (32.0 kg, 94.5 mol, 1.00 eq ) was dissolved in AcOH (80.0 L) and HBr (240 kg, 160 L, 48.0% purity) was added dropwise at 25-40 °C for 30 minutes.
- the reaction mixture was heated at reflux (110 °C) for 24 hours and quenched with water (300 L) at 0 °C.
- the reaction mixture was filtered and the filter cake was treated with EtOH (150 L) at 25 °C for 30 min.
- the reaction mixture was then filtered and the filter cake was dried under reduced pressure to give compound of formula 7 (37.0 kg, 91.7 mol, 96.6% yield) as a red solid.
- a compound of Formula 7 (37.0 kg, 1.00 eq ) and TEA (46.0 kg, 5.00 eq ) were dissolved in dichloromethane (185 L), and PivCl (22.0 kg, 2.00 eq) was added dropwise at 0 ° C for 30 minutes. .
- the reaction mixture was stirred at 25 °C for 12 h and quenched with water (100 L) at 15 °C. Then it was extracted with CH 2 Cl 2 (50 L * 2), the combined organic layers were washed with brine (50 L * 2), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was treated with petroleum ether (150 L) at 25 °C for 30 min.
- the reaction mixture was filtered and the filter cake was dried under reduced pressure to give the compound of formula 8 (30.0 kg, 80.4% yield, 93.8% purity) as a white solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (7)
- (i) 하기 화학식 2의 화합물을 하기 화학식 3의 화합물과 프리델-크래프츠 반응(Friedel-Crafts reaction)시켜 하기 화학식 4의 화합물을 수득하는 단계;(ii) 하기 화학식 4의 화합물을 하기 화학식 5의 화합물과 결합 반응시켜 하기 화학식 6의 화합물을 수득하는 단계;(iii) 하기 화학식 6의 화합물을 탈메틸화 반응시켜 하기 화학식 7의 화합물을 수득하는 단계;(iv) 하기 화학식 7의 화합물을 피바로일 클로라이드와 반응시켜 하기 화학식 8의 화합물을 수득하는 단계;(v) 하기 화학식 8의 화합물을 하기 화학식 9의 화합물과 맥머리 반응(McMurry reaction)시켜 하기 화학식 10의 화합물을 수득하는 단계; 및(vi) 하기 화학식 10의 화합물을 환원 반응시키는 단계를 포함하는 하기 화학식 1의 화합물의 제조방법:[화학식 2][화학식 3][화학식 4][화학식 5][화학식 6][화학식 7][화학식 8][화학식 9][화학식 10][화학식 1]
- 제1항에 있어서, 상기 단계 (i)에서 프리델-크래프츠 반응은 염화알루미늄의 존재 하에 수행되는 제조방법.
- 제1항에 있어서, 상기 단계 (ii)에서 결합 반응은 N-메틸피롤리돈 중에서 탄산칼륨의 존재 하에 수행되는 제조방법.
- 제1항에 있어서, 상기 단계 (iii)에서 탈메틸화 반응은 HBr 및 아세트산을 사용하여 수행되는 제조방법.
- 제1항에 있어서, 상기 단계 (v)에서 맥머리 반응은 TiCl4와 Zn의 존재 하에 수행되는 제조방법.
- 제1항에 있어서, 상기 단계 (vi)에서 환원 반응은 리튬 알루미늄 테트라하이드라이드를 사용하여 수행되는 제조방법.
- 제1항 내지 제6항 중 어느 한 항에 따른 제조방법에 의해 제조된 화학식 1의 화합물을 염화수소와 반응시키는 단계를 포함하는 화학식 1의 화합물의 2염산염의 제조방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280076193.1A CN118251385A (zh) | 2021-11-22 | 2022-11-22 | 制备芳基乙烯化合物的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0161115 | 2021-11-22 | ||
KR1020210161115A KR102694118B1 (ko) | 2021-11-22 | 2021-11-22 | 아릴에텐 화합물의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023090974A1 true WO2023090974A1 (ko) | 2023-05-25 |
Family
ID=86397535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/018469 WO2023090974A1 (ko) | 2021-11-22 | 2022-11-22 | 아릴에텐 화합물의 제조방법 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR102694118B1 (ko) |
CN (1) | CN118251385A (ko) |
WO (1) | WO2023090974A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040081177A (ko) * | 2002-02-05 | 2004-09-20 | 노보 노르디스크 에이/에스 | 신규 아릴- 및 헤테로아릴피페라진 |
KR20180001404A (ko) * | 2016-09-12 | 2018-01-04 | 주식회사 케미메디 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
KR20180001240A (ko) | 2016-06-27 | 2018-01-04 | 주식회사 케미메디 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
KR20210065064A (ko) * | 2019-11-26 | 2021-06-03 | 주식회사 노브메타헬스 | ERRγ 억제제를 유효성분으로 포함하는 항암 효과 증진용 약학적 조성물 |
-
2021
- 2021-11-22 KR KR1020210161115A patent/KR102694118B1/ko active IP Right Grant
-
2022
- 2022-11-22 WO PCT/KR2022/018469 patent/WO2023090974A1/ko active Application Filing
- 2022-11-22 CN CN202280076193.1A patent/CN118251385A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040081177A (ko) * | 2002-02-05 | 2004-09-20 | 노보 노르디스크 에이/에스 | 신규 아릴- 및 헤테로아릴피페라진 |
KR20180001240A (ko) | 2016-06-27 | 2018-01-04 | 주식회사 케미메디 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
KR20180001404A (ko) * | 2016-09-12 | 2018-01-04 | 주식회사 케미메디 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
KR20210065064A (ko) * | 2019-11-26 | 2021-06-03 | 주식회사 노브메타헬스 | ERRγ 억제제를 유효성분으로 포함하는 항암 효과 증진용 약학적 조성물 |
Non-Patent Citations (2)
Title |
---|
KIM JINA, SONG JAEYOUNG, JI HYUN DONG, YOO EUN KYUNG, LEE JAE-EON, LEE SANG BONG, OH JI MIN, LEE SEUNGMI, HWANG JI SUN, YOON HEESE: "Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 62, no. 4, 28 February 2019 (2019-02-28), US , pages 1837 - 1858, XP093008952, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b01296 * |
ZHAO ZHE, TIAN XINZHE, TANG PEICHEN, REN YUN‐LAI, ZHAO SHUANG, ZHENG XIANFU, CHENG XINQIANG: "Autocatalytic Friedel‐Crafts Acylation of Arenes without Additional Catalyst and Additive", CHEMISTRYSELECT, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 6, no. 8, 24 February 2021 (2021-02-24), DE , pages 1772 - 1776, XP093068321, ISSN: 2365-6549, DOI: 10.1002/slct.202100299 * |
Also Published As
Publication number | Publication date |
---|---|
KR102694118B1 (ko) | 2024-08-12 |
CN118251385A (zh) | 2024-06-25 |
KR20230074982A (ko) | 2023-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018308164B2 (en) | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same | |
WO2017023123A1 (ko) | 크로마논 유도체의 신규한 제조방법 | |
WO2016105172A2 (en) | A method for preparing gadobutrol | |
EP3724162A1 (en) | Intermediates for optically active piperidine derivatives and preparation methods thereof | |
WO2019022485A1 (en) | IMPROVED PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES | |
WO2022244969A1 (ko) | 메틸렌 락톤계 화합물의 제조방법 | |
WO2010036048A2 (ko) | 몬테루카스트 나트륨염의 제조방법 | |
WO2023090974A1 (ko) | 아릴에텐 화합물의 제조방법 | |
WO2012050263A1 (en) | Novel method of preparing endoxifen | |
WO2022080812A1 (ko) | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 | |
AU2018308039B2 (en) | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same | |
WO2016076573A2 (ko) | 블로난세린의 제조방법 및 그를 위한 중간체 | |
WO2021107514A2 (ko) | 리피테그라스트의 제조방법 | |
WO2013141437A1 (ko) | 고순도 에스 메토프롤롤의 제조방법 | |
WO2021210920A1 (ko) | 라멜테온의 제조 방법 및 이러한 제조 방법에 이용되는 중간체 화합물 | |
WO2018084625A1 (en) | Method for preparation of (s)-n1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride | |
WO2017074147A1 (en) | Novel process for preparing thienopyrimidine compound and intermediates used therein | |
WO2023013973A1 (ko) | 신규한 루카파립의 제조방법 | |
WO2023013974A1 (ko) | Parp 저해제인 루카파립과 그 중간체의 신규한 제조방법 | |
WO2020085616A1 (ko) | 아픽사반의 제조방법 | |
WO2023167475A1 (ko) | 루카파립의 개선된 제조방법 | |
WO2013154335A1 (ko) | 푸로푸란 리그난 화합물 제조 방법 | |
WO2021112574A1 (en) | A process for preparing isoindolinone derivative, novel intermediates used for the process, and a process for preparing the intermediates | |
WO2020204647A1 (en) | Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | |
AU2019268945B2 (en) | Novel processes for preparing a diaminopyrimidine derivative or acid addition salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22896171 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280076193.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022896171 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022896171 Country of ref document: EP Effective date: 20240624 |